Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Dec 20229:24 amRNSTotal Voting Rights
30th Nov 20227:00 amRNSHikma Injectables Portugal site visit
22nd Nov 202211:38 amRNSHolding(s) in Company
17th Nov 20229:50 amRNSHolding(s) in Company
3rd Nov 20227:00 amRNSTrading Statement
13th Oct 20223:00 pmRNSDirectorate Change
5th Oct 202212:16 pmRNSHolding(s) in Company
4th Oct 202210:05 amRNSHolding(s) in Company
3rd Oct 20223:52 pmRNSBlock listing Interim Review
3rd Oct 20223:11 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSDirector changes and update on AGM 2022 resolution
14th Sep 20229:19 amRNSChange of Hikma interim dividend payment date
1st Sep 20222:25 pmRNSTotal Voting Rights
30th Aug 202212:22 pmRNSHikma launches RYALTRIS
23rd Aug 20223:12 pmRNSDirector/PDMR Shareholding
4th Aug 20227:00 amRNSHalf-year Report
1st Aug 20224:48 pmRNSTotal Voting Rights
18th Jul 20229:26 amRNSNotice of Results
1st Jul 202210:52 amRNSTotal Voting Rights
15th Jun 20223:00 pmRNSCompany Secretary Change
15th Jun 20221:46 pmRNSDirector/PDMR Shareholding
10th Jun 20226:08 pmRNSTransaction in Own Shares
9th Jun 20225:14 pmRNSTransaction in Own Shares
8th Jun 20225:15 pmRNSTransaction in Own Shares
7th Jun 20225:13 pmRNSTransaction in Own Shares
6th Jun 20225:14 pmRNSTransaction in Own Shares
1st Jun 20226:08 pmRNSTransaction in Own Shares
31st May 20225:52 pmRNSTransaction in Own Shares
31st May 202210:00 amRNSDirector/PDMR Shareholding
30th May 20225:23 pmRNSTransaction in Own Shares
27th May 20225:20 pmRNSTransaction in Own Shares
26th May 20225:20 pmRNSTransaction in Own Shares
25th May 20226:03 pmRNSTransaction in Own Shares
24th May 20225:53 pmRNSTransaction in Own Shares
24th May 20227:00 amRNSSiggi Olafsson to step down as Chief Executive
23rd May 20225:51 pmRNSTransaction in Own Shares
20th May 20225:37 pmRNSTransaction in Own Shares
20th May 202212:58 pmRNSResults of EGM
19th May 20226:15 pmRNSTransaction in Own Shares
18th May 20225:22 pmRNSTransaction in Own Shares
17th May 20225:49 pmRNSTransaction in Own Shares
16th May 20226:05 pmRNSTransaction in Own Shares
13th May 20225:41 pmRNSTransaction in Own Shares
12th May 20225:35 pmRNSTransaction in Own Shares
11th May 20225:19 pmRNSTransaction in Own Shares
11th May 20227:00 amRNSShare Buyback Programme
10th May 20225:18 pmRNSTransaction in Own Shares
9th May 20225:59 pmRNSTransaction in Own Shares
6th May 20225:54 pmRNSTransaction in Own Shares
5th May 20225:47 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.